Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
1.
Mult Scler Relat Disord ; 25: 138-142, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-30075406

RESUMO

BACKGROUND: Multiple Sclerosis (MS) and neuromyelitis optica spectrum disorders (NMOSD) are acquired demyelinating syndromes of the central nervous system more frequently in young adults and their beginning before 18 years of age is rare. They are autoimmune diseases with distinct pathophysiology, clinical presentation, treatment and prognoses. During childhood these conditions often present similar clinical features and differential diagnosis among pNMOSD, pMS and acute disseminated encephalomyelitis (ADEM) is still difficult at disease onset. The aim of this article is to describe the epidemiologic and clinical features, to evaluate the response to treatment and to compare the mains characteristics between the patients with MS and NMOSD who had the first event prior to 18 years of age followed at the Universidade Federal de São Paulo (UNIFESP). METHODS: Retrospective analysis of patients with MS and NMOSD who started the disease before 18 years of age followed for at UNIFESP. All patients fulfilled the McDonald 2010 criteria for MS and the IPND 2015 criteria or 2006 diagnostic criteria for NMOSD. For treatment analysis, we select patients with a follow-up of more than 6 months. RESULTS: Sixty-eight patients fulfilled the inclusion criteria for MS and were selected for analysis. Mean age of onset was 15 years, 73.5% were female and the mean follow-up was 6.7 years. Mean annualized relapse rate (aRR) observed was 0,82 relapse/year and mean progression index (PI) was 0.31 EDSS points/year. The multivariate analysis showed a significant association between the EDSS on first appointment and total number of relapses with neurological disabilities in long term in patients with MS. The treatment with interferon-beta (IFN-ß) and glatiramer acetate (GA) was safe and patients treated with high dose IFN-ß and GA had a statistically significant reduction in disability progression. Eleven patients fulfilled the inclusion criteria for NMOSD: mean age of onset was 14 years, 72.7% were female and the mean follow-up was 6.3 years. Mean aRR observed was 1.5 relapse/year and mean PI was 2.2 EDSS points/year. The treatment with azathioprine was safe and significant halts disability progression. Patients with NMOSD reached EDSS 6 prior than those with MS. CONCLUSIONS: Pediatric demyelinating diseases in Brazil are similar to the diseases described abroad. In patients with pMS, the EDSS score at the first appointment and the total number of relapses were associated with poor prognosis. NMOSD is more severe than MS in pediatric patients. Treatment with DMD and azathioprine was well tolerated and effective in reducing relapse rate and disability.


Assuntos
Acetato de Glatiramer/uso terapêutico , Fatores Imunológicos/uso terapêutico , Interferon beta/uso terapêutico , Esclerose Múltipla/tratamento farmacológico , Neuromielite Óptica/tratamento farmacológico , Adolescente , Fatores Etários , Idade de Início , Brasil/epidemiologia , Criança , Pré-Escolar , Avaliação da Deficiência , Feminino , Humanos , Estudos Longitudinais , Masculino , Estudos Retrospectivos , Análise de Sobrevida , Resultado do Tratamento
2.
Arq Neuropsiquiatr ; 73(4): 304-8, 2015 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-25992520

RESUMO

OBJECTIVE: To describe the clinical activities at the Neuroimmunology Clinic of the Universidade Federal de São Paulo (UNIFESP) from 1994 to 2013. METHOD: The final diagnosis of all patients that attended the center was reviewed and established upon specific guidelines for each disease. The number of total appointments and extra clinical activities (reports and prescriptions) were also analyzed, as are part of routine activities. RESULTS: 1,599 patients attended the Clinic from 1994 to 2013: 816 with multiple sclerosis (MS), 172 with clinical isolated syndromes, 178 with neuromyelitis optica (NMO), 216 with other demyelinating disease, 20 with metabolic disorder, 42 with a vascular disease and 155 with other or undetermined diagnosis. A mean 219 outpatient visits and 65 extra clinical activities were performed monthly. CONCLUSION: We identified that 15% of patients seen have NMO. As patients with NMO have a more severe disease than MS, this data may be important for planning local health care policies.


Assuntos
Esclerose Múltipla/epidemiologia , Neuromielite Óptica/epidemiologia , Idade de Início , Brasil/epidemiologia , Estudos Transversais , Doenças Desmielinizantes/diagnóstico , Doenças Desmielinizantes/epidemiologia , Hospitais Universitários/estatística & dados numéricos , Humanos , Doenças Metabólicas/diagnóstico , Doenças Metabólicas/epidemiologia , Esclerose Múltipla/diagnóstico , Neuromielite Óptica/diagnóstico , Fatores de Tempo , Doenças Vasculares/diagnóstico , Doenças Vasculares/epidemiologia
3.
Arq. neuropsiquiatr ; 73(4): 304-308, 04/2015. tab, graf
Artigo em Inglês | LILACS | ID: lil-745749

RESUMO

Objective To describe the clinical activities at the Neuroimmunology Clinic of the Universidade Federal de São Paulo (UNIFESP) from 1994 to 2013. Method The final diagnosis of all patients that attended the center was reviewed and established upon specific guidelines for each disease. The number of total appointments and extra clinical activities (reports and prescriptions) were also analyzed, as are part of routine activities. Results 1,599 patients attended the Clinic from 1994 to 2013: 816 with multiple sclerosis (MS), 172 with clinical isolated syndromes, 178 with neuromyelitis optica (NMO), 216 with other demyelinating disease, 20 with metabolic disorder, 42 with a vascular disease and 155 with other or undetermined diagnosis. A mean 219 outpatient visits and 65 extra clinical activities were performed monthly. Conclusion We identified that 15% of patients seen have NMO. As patients with NMO have a more severe disease than MS, this data may be important for planning local health care policies. .


Objetivo Descrever a casuística de pacientes atendidos no setor de Neuroimunologia da Universidade Federal de São Paulo (UNIFESP) de 1994 a 2013. Método Analisamos o diagnóstico final de todos os pacientes atendidos de 1999 a 2013, sendo o diagnóstico revisado na última consulta e estabelecido de acordo com os critérios específicos para cada doença. O volume de atendimentos clínicos e não clínicos (relatórios e receitas) foram contabilizados para avaliar a carga de trabalho da equipe. Resultados 1.599 pacientes foram avaliados: 816 com esclerose múltipla (EM), 172 com síndromes clínicas isoladas, 178 com neuromielite óptica (NMO), 216 com outras doenças desmielinizantes, 20 com doenças metabólicas, 42 com doenças vasculares e 155 com outros diagnósticos ou diagnósticos indefinidos. Identificamos uma média de 219 consultas e 65 solicitações de relatórios por mês. Conclusão Identificamos que 15% dos pacientes atendidos tem NMO. Por ser uma doença mais incapacitante que a EM estes dados podem ser importantes para o planejamento de políticas de saúde locais. .


Assuntos
Humanos , Esclerose Múltipla/epidemiologia , Neuromielite Óptica/epidemiologia , Idade de Início , Brasil/epidemiologia , Estudos Transversais , Doenças Desmielinizantes/diagnóstico , Doenças Desmielinizantes/epidemiologia , Hospitais Universitários/estatística & dados numéricos , Doenças Metabólicas/diagnóstico , Doenças Metabólicas/epidemiologia , Esclerose Múltipla/diagnóstico , Neuromielite Óptica/diagnóstico , Fatores de Tempo , Doenças Vasculares/diagnóstico , Doenças Vasculares/epidemiologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...